Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Fluticasone Furoate-Vilanterol Decreases COPD Exacerbations in a Pragmatic Trial

Krishnan, Jamuna MD; Zappetti, Dana MD

Clinical Pulmonary Medicine: January 2017 - Volume 24 - Issue 1 - p 54
doi: 10.1097/CPM.0000000000000195
Pulmonary Trends
Buy

Synopsis: Fluticasone furoate-vilanterol has previously been shown to be comparable to existing therapies with regard to improvements in forced Expiratory volume in 1 sec. This study demonstrates that fluticasone furoate-vilanterol reduces Chronic Obstructive Pulmonary Disease exacerbations compared with usual care when studied in a real-world primary care setting.

Source: Vestbo J, Leather D, Bakerly ND, New J et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016.

Disclosure: The authors declare that they have no conflicts of interest.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.